Trials / Completed
CompletedNCT06902103
Pharmacokinetic Study of Single and Multiple Intravenous Administration of Nalbuphine Hydrochloride Injection in Healthy Chinese Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Objective：To evaluate the pharmacokinetic characteristics and safety of single and multiple intravenous injections of nalbuphine hydrochloride injection in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nabufine Hydrochloride Injection | PartA: Nabufine Hydrochloride Injection are administered Intravenous injection single dose |
| DRUG | Nabufine Hydrochloride Injection | PartB: Nabufine Hydrochloride Injection are administered Intravenous injection multi dose |
Timeline
- Start date
- 2023-12-20
- Primary completion
- 2023-12-26
- Completion
- 2024-01-18
- First posted
- 2025-03-30
- Last updated
- 2025-03-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06902103. Inclusion in this directory is not an endorsement.